Author

Gaël S. Roth

h-index 19 View on Semantic Scholar

We have 2 of 78 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

First-line fluoropyrimidine- versus gemcitabine-based chemotherapy for metastatic recurrence after resection of ampullary adenocarcinoma: A real-world analysis of the FFCD-AC cohort.

INTRODUCTION Ampullary adenocarcinoma (AC) is a rare malignancy with limited evidence to guide systemic treatment in the metastatic setting. METHODS This post hoc analysis was conducted within the French national prospective FFCD-AC cohort, which enrolled patients undergoing curative-intent resection for localized AC...

E. Vo-Quang, V. Hautefeuille, O. Bouché et al. · European Journal of Cancer · 0 citations

Review Open access Oct 2026

A pivotal Phase 2 study of derazantinib for previously-treated, locally advanced or metastatic cholangiocarcinoma with FGFR2 aberrations: FIDES-01.

BACKGROUND AIMS To evaluate safety and efficacy of FGFR1-3 kinase inhibitor derazantinib, in advanced intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 fusions or rearrangements (FGFR2F), mutations (FGFR2M), or amplifications (FGFR2A), previously treated with chemotherapy. APPROACH RESULTS Open-label, non-contro...

M. Borad, Michele Droz Dit Busset, M. Javle et al. · Hepatology · 0 citations